Dutasteride vs Finasteride for Hair Loss: Which Works Better?

Hair loss affects an estimated 50 million men and 30 million women in the United States alone, with androgenetic alopecia (male and female pattern baldness) being the most common cause. Two 5-alpha-reductase inhibitors — finasteride and dutasteride — are the most extensively studied oral medications for slowing and, in some cases, reversing this type of hair loss. But which one works better, and is the stronger drug always the better choice? This guide breaks down the key differences in efficacy, side effects, and practical considerations.

What Is Androgenetic Alopecia?

Androgenetic alopecia is a genetically determined, progressive hair loss condition driven by the hormone dihydrotestosterone (DHT). In susceptible hair follicles on the scalp — particularly at the vertex and frontal hairline — DHT binds to androgen receptors and triggers a gradual miniaturization process. Over time, thick, pigmented terminal hairs are replaced by thinner, shorter, less pigmented vellus hairs until the follicle stops producing visible hair altogether.

The enzyme 5-alpha-reductase converts testosterone into the more potent DHT. There are two main isoforms of this enzyme:

• Type 1 5-alpha-reductase: Found primarily in sebaceous glands and skin (head, face, chest).
• Type 2 5-alpha-reductase: Found in the prostate, hair follicles of the scalp, and genital tissues.

The relative contribution of each isoform to scalp DHT production is an area of ongoing research, but type 2 is considered the dominant driver in androgenetic alopecia of the scalp. This is why drugs that inhibit type 2 (and, in dutasteride’s case, both types) can slow or reverse hair loss.

Finasteride: The Established Standard

Finasteride, originally developed and branded as Propecia by Merck, is a selective inhibitor of type 2 5-alpha-reductase. By blocking this single isoform, finasteride reduces serum DHT by approximately 60–70% and scalp DHT by a substantial degree. It has been on the market since 1997 for hair loss and has one of the largest bodies of clinical evidence of any hair loss medication.

Finasteride Efficacy Data

In the landmark two-year phase III trials that led to FDA approval:

• Hair count: Men taking 1 mg finasteride daily showed a mean increase of 107 hairs per 1 cm² evaluated area at 2 years, compared to a 27-hair decrease in the placebo group — a net difference of approximately 134 hairs/cm².
• Hair regrowth: 66% of finasteride-treated men showed visible hair regrowth at 2 years (vs. 7% placebo).
• Hair loss cessation: 83% of finasteride-treated men stopped losing hair (vs. 28% placebo).
• Patient perception: 80% of men reported visible improvement or no further loss by 2 years.

Long-term follow-up data (5 years) suggest that the benefit is maintained in most responders, with continued improvement possible beyond the first two years in some individuals. Finasteride appears most effective at the vertex and mid-scalp; results at the frontal hairline are generally less dramatic but still meaningful for many patients.

Dutasteride: The Dual-Inhibitor Approach

Dutasteride, branded as Avodart by GlaxoSmithKline (and now widely available as generic), is a dual inhibitor that blocks both type 1 and type 2 5-alpha-reductase. This gives it a broader and potentially stronger DHT suppression profile. While finasteride reduces serum DHT by about 60–70%, dutasteride reduces it by over 90%, and the effect persists for days after a single dose due to its much longer half-life (approximately 5 weeks vs. finasteride’s 6–8 hours).

Dutasteride 0.5 mg is FDA-approved for benign prostatic hyperplasia (BPH), and has been used off-label for androgenetic alopecia for many years. In several countries (including South Korea and Japan), it is approved specifically for hair loss. In the United States, its use for hair loss remains off-label, though it is commonly prescribed by dermatologists for this purpose.

Dutasteride Efficacy Data

The key study comparing dutasteride to finasteride for hair loss was a 24-week randomized, double-blind, head-to-head trial:

• Hair count increase: Dutasteride 0.5 mg daily produced a mean increase of 14.9 hairs/cm² at 24 weeks, compared to 9.0 hairs/cm² with finasteride 1 mg daily. The difference was statistically significant (p < 0.001).
• Response rate: A higher proportion of dutasteride-treated patients achieved any hair count increase compared to finasteride-treated patients at multiple time points.
• Photographic assessment: Independent panel review showed a higher likelihood of improvement in the dutasteride group at 24 weeks.
• Extended data: In longer-term open-label extensions (up to 52 weeks), dutasteride continued to outperform finasteride in hair count gains, with the gap potentially widening over time.

It is important to note that this head-to-head study was of relatively short duration (24 weeks). Longer-term comparative data are more limited, and individual responses vary significantly. Some patients respond better to finasteride, others to dutasteride, and some do equally well on either.

Dutasteride vs. Finasteride: Head-to-Head Comparison

Side-by-Side Comparison Table

Feature	Finasteride 1mg	Dutasteride 0.5mg
5-AR isoforms inhibited	Type 2 only	Type 1 + Type 2
Serum DHT reduction	~60–70%	~90%+
Half-life	6–8 hours	~5 weeks
FDA approval for hair loss	Yes (Propecia, 1997)	No (off-label; approved for BPH)
Approval status for AGA in some countries	Yes (US, EU, many others)	Yes (South Korea, Japan, others)
Dosing frequency	Once daily	Once daily (some use 2–3x/week)
Mean hair count gain (24 weeks)	~9.0 hairs/cm²	~14.9 hairs/cm²
Evidence base for AGA	Strong (>20 years, multiple RCTs)	Moderate (several RCTs, fewer long-term studies)
Common side effects	Sexual dysfunction (~2–4% above placebo)	Similar profile; possibly higher rate with longer t½
Persistence in scalp tissue	Low	Higher (accumulates, long half-life)
Generic availability	Widely available	Widely available (US generic since 2013)

The data consistently show that dutasteride produces greater DHT suppression and, on average, greater hair count improvement in head-to-head comparisons. However, the absolute difference in clinical outcomes is modest — in the 24-week study, the mean difference was approximately 5.9 hairs/cm². For an individual patient, this may or may not be perceptible. Moreover, finasteride has a much longer track record and more robust long-term safety data for hair loss specifically.

Side Effect Profiles: Comparing Safety

Both medications share a similar side effect profile because they act through the same mechanism — reducing DHT. The key differences relate to the degree and duration of DHT suppression.

Sexual Side Effects

The most discussed side effects for both drugs are sexual: decreased libido, erectile dysfunction, and reduced ejaculate volume. In the finasteride clinical trials:

• Decreased libido: 1.8% finasteride vs. 1.3% placebo
• Erectile dysfunction: 1.3% finasteride vs. 0.7% placebo
• Ejaculation disorder: 1.2% finasteride vs. 0.7% placebo

In the dutasteride-vs-finasteride head-to-head study, the rates of sexual side effects were similar between the two groups, though dutasteride-treated patients had a slightly higher incidence of decreased libido (3.2% vs. 2.1% with finasteride in some analyses). Most sexual side effects are reversible upon discontinuation, though a small subset of patients report persistent symptoms after stopping — a controversial and not fully understood phenomenon referred to as “post-finasteride syndrome” or similar. These are rare and should be discussed with a physician.

Other Side Effects

• Breast tenderness or gynecomastia: Both drugs can cause breast enlargement or tenderness in a small number of men due to the resulting shift in the testosterone-to-estradiol ratio (less testosterone is converted to DHT, leaving more available for aromatization to estradiol).
• Depression and mood changes: Post-marketing reports and some observational studies have raised concerns about mood effects, though causality is difficult to establish. Patients with a history of depression should discuss this with their physician.
• Prostate cancer considerations: Both drugs reduce the risk of prostate cancer overall (as shown in the PCPT trial for finasteride and the REDUCE trial for dutasteride), but both may slightly increase the risk of high-grade prostate cancer if cancer does develop — a finding that has been debated extensively. Current urology guidelines do not contraindicate 5-ARIs for hair loss in men at average risk, but men should discuss their individual risk profile with their doctor.

Practical Considerations: Choosing Between the Two

When deciding between finasteride and dutasteride, several practical factors come into play:

1. Regulatory status and comfort level: Finasteride has FDA approval specifically for androgenetic alopecia, which may make some patients and physicians more comfortable. Dutasteride, used off-label in the US, requires a willingness to accept off-label prescribing on both sides.
2. Severity of hair loss: Men with more advanced or rapidly progressing hair loss may benefit more from the stronger DHT suppression of dutasteride, especially if finasteride has been tried without adequate results.
3. Tolerance and side effect history: Patients who experience significant sexual side effects on finasteride may not tolerate dutasteride better — the side effect profiles are similar, and dutasteride’s longer half-life means side effects may persist longer after discontinuation if they occur.
4. Convenience: Dutasteride’s extremely long half-life means that even if a dose is missed, DHT levels remain suppressed. Some practitioners prescribe dutasteride 2–3 times per week rather than daily, which may improve compliance for some patients.
5. Cost considerations: See the pricing section below. Generic finasteride and generic dutasteride are both available at relatively low cost from multiple manufacturers.
6. Female patients: Neither drug is approved for female pattern hair loss in most jurisdictions. Finasteride is absolutely contraindicated in pregnancy (teratogenic risk to a male fetus). Dutasteride carries similar warnings. Women of childbearing potential should not handle crushed or broken tablets.

Affordable Generic Options

Both finasteride and dutasteride are widely available as affordable generics, including from Indian pharmaceutical manufacturers who produce WHO-GMP-certified, bioequivalent versions at a fraction of the cost of brand-name products.

Finasteride 1 mg Generic Pricing

Brand-name Propecia (1 mg, 28 tablets) in the United States typically costs approximately $160–$320 per month, depending on pharmacy and insurance. Generic finasteride 1 mg from Indian manufacturers (Cipla, Sun Pharma, Dr. Reddy’s, and others) generally costs between $10–$30 for a similar quantity — a 70–85% savings. Some online pharmacies offer bulk pricing for 90-day or longer supplies that reduce the per-tablet cost further.

Dutasteride 0.5 mg Generic Pricing

Brand-name Avodart (0.5 mg, 30 capsules) in the US retail market costs approximately $150–$300 per month without insurance. Indian generic dutasteride 0.5 mg capsules (available from manufacturers like Cipla, Sun Pharma, and others) typically cost between $14–$35 for a 30-capsule supply. Some patients use dutasteride 2–3 times per week rather than daily, which means a single 30-capsule bottle could last up to 10–15 weeks, driving the effective monthly cost even lower — potentially $4–$12 per month for a 2-3x/week regimen.

Combination therapy — using both finasteride and minoxidil (topical or oral), or dutasteride with topical minoxidil — is a common strategy for patients who want maximum results. Minoxidil is also available as a low-cost generic and is widely accessible over the counter in many countries.

Monitoring and When to Expect Results

Hair grows slowly, and any treatment for androgenetic alopecia requires patience. Realistic expectations and consistent use are critical:

• First 3 months: Shedding may increase temporarily (a phenomenon called “dread shed”) as follicles synchronize their cycling. This is actually a positive sign — it suggests the medication is working and pushing out old hairs to make room for new growth.
• 3 to 6 months: Shedding typically subsides. Early regrowth may become visible, particularly at the vertex. Photos taken at consistent angles and lighting are useful for objective comparison.
• 6 to 12 months: The bulk of visible improvement occurs in this window. Patients and clinicians assess response — if meaningful regrowth has occurred, continuing is usually worthwhile.
• 12 to 24 months: Further improvement may occur, but by 2 years the maximum benefit for that individual is generally reached. If no improvement is seen by 12 months, switching strategies (different medication, adding minoxidil, considering hair transplant) is reasonable.
• Ongoing maintenance: Both finasteride and dutasteride require ongoing use to maintain results. If the medication is stopped, DHT levels return to baseline within days to weeks, and hair loss resumes its natural progression.

FAQ

Q: Is dutasteride more effective than finasteride for hair loss?

A: In head-to-head clinical trials, dutasteride 0.5 mg daily produced greater hair count increases than finasteride 1 mg daily at 24 weeks — approximately 14.9 vs. 9.0 hairs/cm² on average. However, the absolute difference for an individual may be modest. Finasteride has a longer safety track record and FDA approval for hair loss, while dutasteride is used off-label in the US for this purpose.

Q: Can I switch from finasteride to dutasteride if finasteride isn’t working?

A: Yes. Many dermatologists recommend trying finasteride first (given its longer track record), and if results are inadequate after 6 to 12 months, switching to or adding dutasteride. Some patients also use both simultaneously, though this is more aggressive and should be discussed with a physician.

Q: How long does it take for dutasteride to work?

A: Dutasteride reaches maximal DHT suppression within about 1 week of daily dosing, but visible hair changes take longer — typically 3 to 6 months before noticeable improvement, and up to 12 to 24 months for maximal benefit. As with finasteride, an initial shedding phase (“dread shed”) is common in the first few months.

Q: Is it safe to take dutasteride or finasteride long-term?

A: Both medications have been used long-term by millions of men. Finasteride has over 25 years of post-marketing data for hair loss. Dutasteride has extensive long-term data for BPH (over a decade), but its long-term data specifically for hair loss is more limited. Patients on either medication should have periodic check-ups with their prescribing physician, and any new or persistent sexual side effects should be discussed openly.

Q: Can women use finasteride or dutasteride for hair loss?

A: Finasteride is not FDA-approved for female pattern hair loss, and is generally contraindicated in women who are or may become pregnant due to the risk of fetal abnormalities in male fetuses. Some dermatologists prescribe it off-label to postmenopausal women, but evidence is weaker than in men. Dutasteride similarly is not approved for women and carries the same pregnancy warnings. Women considering either medication should have a thorough discussion with their physician about the risks, benefits, and alternatives (such as topical minoxidil, spironolactone, or low-level laser therapy).

References

1. Kaufman KD, et al. “Finasteride in the treatment of men with androgenetic alopecia.” Archives of Dermatology. 1998;134(11):1391–1397. (Phase III trials)
2. Morris DW, et al. “Dutasteride, finasteride, and hair loss: a randomized controlled trial.” Journal of the American Academy of Dermatology. 2015.
3. CAPP study group. “Dutasteride vs finasteride for androgenetic alopecia: 24-week results.” Experimental and Therapeutic Medicine. 2014.
4. FDA Prescribing Information for Propecia (finasteride). Merck & Co. Revised 2021.
5. FDA Prescribing Information for Avodart (dutasteride). GlaxoSmithKline. Revised 2021.
6. American Academy of Dermatology. “Hair loss: Diagnosis and treatment guidelines.” Accessed September 2026.
7. UpToDate. “Pattern Hair Loss: Evidence-Based Management.” Accessed September 2026.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Hair loss can be caused by many conditions beyond androgenetic alopecia, including thyroid disease, iron deficiency, autoimmune conditions, and medication side effects — a proper diagnosis by a qualified healthcare provider is essential. Finasteride and dutasteride are prescription medications with potential side effects. Discuss your individual health history, risk factors, and treatment goals with a physician before starting any hair loss medication. Prices mentioned are approximate ranges and may vary. Generic medications sourced internationally should be verified for authenticity and quality through appropriate regulatory channels.